Mechanism of Action
In a recently published peer-reviewed study, the active constituents found in UriLess, which has garnered approval from Health Canada for the treatment of Overactive Bladder (OAB) and Urinary Incontinence (UI), demonstrated a significant amelioration in the symptoms associated with overactive bladder syndrome. The clinical research not only confirmed the therapeutic potential of UriLess but also offered profound insights into its pharmacodynamic properties. Mechanism of Action
Diving deeper into the study's findings, the mechanism of action of UriLess was extensively evaluated. The research team observed a remarkable decrease in both basal pressure and the detrusor overactivity index. This is crucial as these parameters are key indicators of bladder health and function. Moreover, the study documented favorable elevations in threshold pressure, voided volume, intercontraction interval, and bladder compliance. These results collectively signify enhanced bladder functionality and underscore the potential of UriLess as a leading therapeutic intervention for OAB and UI.
